Phase 2 Rheumatoid Arthritis Trial, Recruiting NCT06805448 Sponsor: Rigshospitalet, Denmark Condition: Rheumatoid Arthritis
Back to Rheumatoid Arthritis

Phase 2 Rheumatoid Arthritis Trial, Recruiting

NCT06805448
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with Sjögren's disease (a condition that affects moisture-producing glands) according to internationally recognised classification standards
  • People who are 18 years of age or older
  • People who have experienced persistent dry mouth for at least 3 months
  • People whose saliva production falls within a specific measurable range — not too low and not too high (confirm with trial site for exact measurements)
  • People who are able to understand the trial information and are willing to sign a written consent form

Who may not be able to join:

  • People who are currently taking certain medications known to cause dry mouth, such as some antidepressants, opioid painkillers, or certain blood pressure medicines
  • People who have another condition affecting the salivary glands, such as dry mouth caused by radiation treatment
  • People who have previously had surgery on the submandibular gland (a saliva gland under the jaw)
  • People who have previously received any type of stem cell treatment in the salivary glands
  • People who are pregnant, or planning to become pregnant within the 12-month study period
  • People who are currently breastfeeding
  • People who have smoked tobacco within the 6 months before the screening visit
  • People who currently drink more than 10 units of alcohol per week
  • People who have any other health condition that the trial investigator considers a reason for exclusion (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +4523312552

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
21 January 2025
Est. completion
1 December 2025

Where this trial is recruiting

🇩🇰 Denmark

Primary endpoints

Change in unstimulated whole saliva flow rate by sialometry

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov